Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity [Yahoo! Finance]
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]